Loredana Bălăcescu - Genetic Mutations

Author Information

Loredana Bălăcescu is a distinguished researcher affiliated with The Oncology Institute "Prof. Dr. Ion Chiricuta", specifically within the Department of Genetics, Genomics, and Experimental Pathology, located at 34-36 Republicii Street, Cluj-Napoca, Romania. Her research predominantly revolves around cancer genomics, with significant contributions to the understanding and treatment of various cancer types, particularly colorectal and prostate cancer.

Research Contributions

Loredana Bălăcescu has made substantial contributions to cancer research, focusing on biomarkers and therapeutic strategies. In 2021 alone, she authored several influential papers, including studies on long noncoding RNA NEAT1 as a biomarker for prostate cancer, the efficacy of doubling the dose of Bevacizumab in metastatic colorectal cancer, and the development of large-scale PCR testing protocols for SARS-CoV-2. Her work also explores the role of circulating miRNAs as biomarkers for treatment response in metastatic colorectal cancer and investigates novel approaches to chemotherapy and supportive care for cancer patients.

Aliases

Loredana Bălăcescu is also known by several aliases, including L Balacescu and Loredana Balacescu.

Publication and Citation Metrics

Metric	Value
Citation Count	810
H-index	15
Paper Count	74

Publications:

Long Noncoding RNA NEAT1 as a Potential Candidate Biomarker for Prostate Cancer

DOI: 10.3390/life11040320

Year: 2021

Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer–the Experience of a Tertiary Cancer Center

DOI: 10.3389/fphar.2021.487316

Year: 2021

Critical Aspects Concerning the Development of a Pooling Approach for SARS-CoV-2 Diagnosis Using Large-Scale PCR Testing

DOI: 10.3390/v13050902

Year: 2021

Predictive Efficacy of MiR-125b-5p, MiR-17-5p, and MiR-185-5p in Liver Metastasis and Chemotherapy Response Among Advanced Stage Colorectal Cancer Patients

DOI: 10.3389/fonc.2021.651380

Year: 2021

Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis

DOI: 10.1371/journal.pone.0248922

Year: 2021

Decrease of oncological patients' hospital visits during Covid-19 pandemic; the experience of a tertiary Romanian centre.

DOI: 10.1200/JCO.2021.39.15_SUPPL.E13607

Year: 2021

Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors—A Breakthrough in the Treatment of Cancer Patients with Febrile Neutropenia

DOI: 10.3390/medicina57070675

Year: 2021

Treatment beyond progression in metastatic colorectal cancer: to double or not to double the dose of bevacizumab?

DOI:

Year: 2020

Current and New Predictors for Treatment Response in Metastatic Colorectal Cancer. The Role of Circulating miRNAs as Biomarkers

DOI: 10.3390/ijms21062089

Year: 2020

A new desensitization protocol, overcoming hypersensitivity reactions to chemotherapy.

DOI: 10.1200/jco.2020.38.15_suppl.e15523

Year: 2020

What Are the Ethical Considerations for CRISPR Technology?

How Do Genetic Mutations Affect Vaccine Efficacy?

How Are Genetic Diseases Diagnosed?

What Makes a Mutation Harmful?

What Causes CNVs?

What is Genetic Testing for BRCA1 and BRCA2?

What is the Role of Precision Medicine in This Context?

What are Autism Spectrum Disorders?

What Are the Common PARP Inhibitors?

How Do Genetic Mutations Cause Developmental Disorders?

Partnered Content Networks

Relevant Topics